# US DNA Synthesis Market

> US DNA Synthesis Market Research Report: Size, Share, Trend Analysis By Applications (Gene Therapy, Synthetic Biology, Molecular Diagnostics, Vaccine Development), By Product Type (Oligonucleotides, Gene Fragments, Gene Libraries), By End Users (Academic Research Institutions, Pharmaceutical Companies, Biotechnology Companies, Clinical Laboratories) and By Technology (Solid-Phase Synthesis, Liquid-Phase Synthesis, PCR-Based Synthesis) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 30.75%
- **2024:** $ 888.64 Million
- **2025:** $ 1,161.9 Million
- **2035:** $ 16,960.94 Million
- **Key Players:** Thermo Fisher Scientific (US), Illumina (US), Integrated DNA Technologies (US), Eurofins Genomics (DE), GenScript (CN), Twist Bioscience (US), Synthetic Genomics (US), Bioneer (KR), DNA Script (FR)

**Report ID:** MRFR/HC/51009-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-dna-synthesis-market-52769

---

## Market Summary

## **US DNA Synthesis Market Overview**

As per MRFR analysis, the US DNA Synthesis Market Size was estimated at 1.04 (USD Billion) in 2023.The US DNA Synthesis Market Industry is expected to grow from 1.13(USD Billion) in 2024 to 3.03 (USD Billion) by 2035. The US DNA Synthesis Market CAGR (growth rate) is expected to be around 9.343% during the forecast period (2025 - 2035)

**Key US DNA Synthesis Market Trends Highlighted**

The US DNA synthesis market is experiencing notable trends driven by various factors. A significant market driver is the increasing demand for synthetic DNA across various sectors, particularly in biotechnology and pharmaceuticals. The growing focus on personalized medicine has led to a rising requirement for tailored genomic solutions, fueling the synthesis of DNA for research and therapeutic applications. Furthermore, advancements in sequencing technologies and synthetic biology techniques are amplifying the efficiency and capability of DNA synthesis, making it more accessible to researchers and companies alike.

Opportunities in the US DNA synthesis market are abundant, particularly with the ongoing research initiatives supported by government funding, such as those from the National Institutes of Health (NIH) and the Department of Energy (DOE). These initiatives aim to promote advancements in genomic research, biotechnology innovations, and even agricultural biotechnology, creating market space for new entrants and established firms looking to expand their capabilities. Recent trends indicate a growing collaboration between academic institutions and private companies in the DNA synthesis space.

This collaboration often focuses on developing new applications for healthcare and agricultural purposes, combining academic research with practical industrial applications. Additionally, there is increasing interest in issues like biosecurity and ethical considerations surrounding synthetic biology, further shaping the landscape of the DNA synthesis market in the US. As the market matures, regulatory frameworks are also evolving, ensuring that innovations align with public health and safety standards, which is crucial for gaining public acceptance and further driving growth in the sector.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**US DNA Synthesis Market Drivers**

**Increase in Biopharmaceutical Development**

One major factor propelling the US DNA Synthesis Market Industry is the expansion of the biopharmaceutical industry in the US. With over 300 businesses engaged in the development of novel treatments, the Biotechnology Innovation Organization claims that the US leads the world in biopharmaceutical research. According to the National Institutes of Health, funding for biopharmaceutical research and development (R&D) increased by 30% between 2015 and 2020, with an estimated USD 42 billion spending in 2020 alone. The need for synthetic DNA is increased by this increased research effort, as sophisticated medications increasingly need specific genetic components to work.

As a result, it is anticipated that the biopharmaceutical boom would greatly increase the US DNA Synthesis Market.

**Advancements in Genomic Research**

The push for genomic research, particularly in the areas of personalized medicine and genetic therapies, serves as a critical driver for the US DNA Synthesis Market Industry. The Human Genome Project, initiated over two decades ago, sparked immense growth in genetic research, with the National Human Genome Research Institute estimating that the cost of sequencing a human genome has plummeted from nearly 3 billion USD to under 1,000 USD. This democratization of genomic information promotes research and clinical applications that rely heavily on synthetic DNA.

As universities and biotech firms ramp up their research and development efforts, the reliance on synthesized DNA continues to rise, boosting the market prospects.

**Growing Applications in Synthetic Biology**

The US DNA Synthesis Market Industry is also benefiting from the expanding applications in synthetic biology. According to data from the U.S. Department of Energy, synthetic biology could contribute up to 10% of the global economy by 2030, translating to potential economic impacts in the range of 3.2 trillion USD. This growth is driven by innovations across sectors such as agriculture, energy, and biomanufacturing, all of which utilize synthesized DNA for developing more efficient biological systems.

Research institutions like MIT and Stanford University are at the forefront of these developments, offering programs that actively promote the commercialization of synthetic biology, thereby driving the demand for DNA synthesis.

**Increase in Genetic Testing and Diagnostics**

The increased emphasis on genetic testing and diagnostics is a pivotal driver for the US DNA Synthesis Market Industry. According to the Centers for Disease Control and Prevention, genetic testing for inherited conditions has seen over a 50% increase in utilization in the last decade, indicating a growing trend among healthcare providers and patients. This trend is supported by the fact that early and personalized diagnostic testing has shown significant benefits in patient outcomes and treatment effectiveness.

Consequently, laboratories and healthcare institutions are increasingly investing in advanced DNA synthesis technologies to meet the escalating needs for efficient and accurate genetic diagnostics, thereby propelling market growth.

**US DNA Synthesis Market Segment Insights**

**DNA Synthesis Market Application Insights  **

The Application segment of the US DNA Synthesis Market holds significant value, with diverse applications ranging from Gene Therapy to Vaccine Development. This market is driven by the rapid advancements in biotechnology and a growing demand for precision medicine, impacting the overall landscape in profound ways. In Gene Therapy, the focus is on using engineered DNA to modify or repair genes, offering promising treatments for genetic disorders. This area is gaining momentum due to its potential to revolutionize the clinical approach to previously untreatable diseases.

Similarly, Synthetic Biology leverages DNA synthesis to create new biological parts and systems, attracting substantial investment and interest for its ability to tackle challenges like biofuel production and agricultural enhancements. Molecular Diagnostics, meanwhile, is rapidly evolving, utilizing synthesized DNA to improve the accuracy and speed of disease detection, particularly in areas like oncology and infectious diseases, highlighting its crucial role in modern healthcare. Lastly, Vaccine Development has witnessed significant growth, especially in response to recent global health challenges, with DNA synthesis enabling faster and more efficient vaccine formulations.

The interplay of these applications illustrates the dynamic nature of the US DNA Synthesis Market, driven by innovation and a response to urgent health needs, ensuring relevance in both research and clinical settings. Overall, the market is characterized by its robust activity, aiming to address some of the most pressing health issues, demonstrating its vital role in the broader context of biomedicine and public health strategy.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**DNA Synthesis Market Product Type Insights  **

The US DNA Synthesis Market is characterized by its diverse Product Type offerings, primarily including Oligonucleotides, Gene Fragments, and Gene Libraries, each playing a crucial role in various applications across Research and Development, diagnostics, and therapeutic developments. Oligonucleotides are pivotal in gene editing and molecular diagnostics, often considered the backbone of synthetic biology due to their versatility in targeting specific genetic sequences. Gene Fragments contribute significantly to the creation of recombinant proteins and gene therapies, enabling advancements in personalized medicine.

Meanwhile, Gene Libraries serve as essential tools for genetic research, providing a vast reservoir of genetic materials that aid in discovering new genes and their functions. The market dynamics reflect an increasing dependency on these products to support innovations in genomics and biotechnology, driven by rising investments in genetic research. This collective growth indicates a trend toward higher integration of genomic solutions in healthcare, fueling overall market expansion within the US.

**DNA Synthesis Market End User Insights  **

The End User segment of the US DNA Synthesis Market showcases a diverse array of applications across various industries, highlighting its critical role in advancing genetic research and biotechnology. Academic Research Institutions are integral in driving innovation, focusing on fundamental DNA research and engaging in educational pursuits that lay the groundwork for future advancements. Pharmaceutical Companies leverage DNA synthesis for drug development, utilizing synthesized DNA for therapeutic uses and ensuring robust pipeline growth.

Biotechnology Companies are pivotal as they implement DNA synthesis in the creation of genetically modified organisms and in the development of cutting-edge therapies, underlining their significance in addressing health challenges. Meanwhile, Clinical Laboratories are essential for diagnostic applications, employing synthesized DNA in genetic testing and personalized medicine, thus catering to the growing demand for tailored healthcare solutions. As a result, the US DNA Synthesis Market segmentation into these varied End Users reflects not only current technological trends but also the potential for future growth driven by advancements in genetic engineering and bioinformatics.

Overall, this segment is poised for significant evolution as it addresses both academic inquiries and real-world health issues across multiple sectors.

**DNA Synthesis Market Technology Insights  **

The Technology segment of the US DNA Synthesis Market is characterized by diverse methodologies that facilitate precise DNA production. Solid-Phase Synthesis is known for its robustness, enabling efficient assembly of custom oligonucleotides, which play a crucial role in Research and Development across various applications such as diagnostics and therapeutics. Similarly, Liquid-Phase Synthesis offers flexibility and scalability, making it suitable for large-scale projects in genomics and synthetic biology, where rapid results are essential. PCR-Based Synthesis is significant due to its widespread use in amplifying DNA fragments, instrumental in fields like genetic research and biotechnology.

This segment has garnered immense attention owing to increasing demands for synthetic biology applications and advancements in genomic studies, reflecting a strong growth trajectory within the US. Moreover, the rise in personalized medicine and biopharmaceuticals further catalyzes the utility of these synthesis technologies, signifying their pivotal role in transforming scientific research and applications in the healthcare and agriculture sectors. As this segment continues to evolve, it presents ample opportunities for innovation and expansion, positioning itself at the forefront of the US DNA Synthesis Market industry.

**US DNA Synthesis Market Key Players and Competitive Insights**

The US DNA Synthesis Market has witnessed a remarkable evolution driven by advancements in biotechnology, increasing demand for personalized medicine, and the growing necessity for genetic research and synthetic biology applications. As this market expands, numerous players have emerged, each vying for competitive positioning through innovation, quality of service, and strategic partnerships. The competitive landscape is marked by both established and emerging firms that cater to various sectors, including academic research, pharmaceuticals, and agriculture. Organizations are leveraging cutting-edge technologies to enhance synthesis capabilities while addressing the complexities of customer requirements.

As this dynamic environment continues to develop, understanding the competitive insights is crucial for firms aiming to excel and differentiate themselves within the marketplace. Agilent Technologies stands out in the US DNA Synthesis Market due to its strong commitment to providing high-quality synthesis solutions tailored to meet diverse customer needs. The company boasts a comprehensive portfolio that covers an array of applications from gene synthesis to custom oligonucleotide production. Agilent's state-of-the-art manufacturing facilities enable it to maintain rigorous quality control, ensuring the reliability and performance of its products.

The company's strategic focus on research and development has also led to significant advancements in synthesis technologies, enhancing its ability to deliver rapid turnaround times and scalable solutions. Agilent Technologies leverages its extensive distribution networks to maintain a robust market presence, allowing it to effectively reach various sectors, including genomics, diagnostics, and therapeutics. Furthermore, its legacy of innovation and commitment to customer service have solidified its reputation as a leading player in the industry.

Eurofins Genomics solidifies its position in the US DNA Synthesis Market by providing a range of high-quality synthetic products and services that cater to the needs of researchers and organizations in various fields. The company specializes in gene synthesis, oligos, and sequencing services, focusing on delivering fast and reliable results to meet the demands of modern scientific endeavors. Eurofins Genomics has strategically expanded its services through mergers and acquisitions, enhancing its capabilities and market footprint within the US.

Their emphasis on quality assurance and technical support ensures that clients receive not only the products but also the expertise needed to drive their projects forward. Additionally, Eurofins Genomics maintains a commitment to innovation, continuously seeking advancements in its processes and technologies. This proactive approach, combined with the company's strong relationships in academia and industry, underscores its vital role in the competitive landscape of the US DNA Synthesis Market, positioning it favorably against its rivals.

**Key Companies in the US DNA Synthesis Market Include**

**US DNA Synthesis Market Industry Developments**

The US DNA Synthesis Market has seen notable advancements and developments recently. In September 2023, Agilent Technologies announced its expansion of synthetic biology capabilities, strengthening its position within the market and enhancing service offerings for clients. Concurrently, Thermo Fisher Scientific introduced new advancements to its GeneArt suite, enabling faster and more efficient DNA synthesis, which is likely to contribute to increasing market demand. Merger and acquisition activities are also noteworthy, with Twist Bioscience acquiring a leading synthetic biology firm in August 2023, thereby broadening its product portfolio.

In the past couple of years, the market has witnessed significant growth, with a substantial increase in demand for custom DNA synthesis services due to rising investments in biotechnology and genomics, aligning with initiatives by the US government to promote innovation in life sciences. Companies like Illumina and Integrated DNA Technologies continue to expand their market presence through strategic collaborations and new product launches that address diverse needs within genomic research and therapeutic development. Overall, these factors contribute to a dynamic landscape in the US DNA Synthesis Market, reflective of ongoing technological advancements and increased applications in various sectors.

**DNA Synthesis Market Segmentation Insights**

## Market Drivers

### Emergence of Synthetic Genomics

The emergence of synthetic genomics is reshaping the landscape of the DNA Synthesis Market, as it focuses on the design and construction of entire genomes. This innovative approach has the potential to revolutionize various industries, including healthcare, energy, and materials. The synthetic genomics market is anticipated to grow significantly, with estimates suggesting a value of $5 billion by 2028 in the US. This growth is driven by the increasing interest in creating custom organisms for specific applications, which necessitates advanced dna synthesis capabilities. As research in synthetic genomics progresses, the dna synthesis market is likely to expand, providing new opportunities for companies involved in this cutting-edge field.

### Advancements in Synthetic Biology

The DNA Synthesis Market is experiencing a surge due to advancements in synthetic biology, which enables the design and construction of new biological parts and systems. This field has seen substantial investment, with funding reaching approximately $1.5 billion in the US in recent years. These innovations facilitate the development of novel therapeutics, biofuels, and agricultural products, thereby expanding the applications of dna synthesis. As researchers continue to explore the potential of synthetic biology, the demand for high-quality, cost-effective dna synthesis services is likely to increase. This trend indicates a robust growth trajectory for the dna synthesis market, as companies strive to meet the evolving needs of the biotechnology sector.

### Growing Demand for Gene Therapies

The increasing prevalence of genetic disorders and the rising interest in gene therapies are driving the DNA Synthesis Market. In the US, the gene therapy market is projected to reach $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of over 30%. This growth is fueled by the need for innovative treatment options that address previously untreatable conditions. As gene therapies rely heavily on precise dna synthesis for the development of therapeutic agents, the market is poised for expansion. The collaboration between pharmaceutical companies and dna synthesis providers is likely to enhance the efficiency and effectiveness of gene therapy development, further propelling the dna synthesis market.

### Rising Applications in Agriculture

The application of dna synthesis in agriculture is becoming increasingly prominent, driven by the need for sustainable farming practices and food security. The market for genetically modified organisms (GMOs) is projected to reach $40 billion by 2027 in the US, indicating a significant opportunity for dna synthesis providers. These applications include the development of crops with enhanced traits such as pest resistance and improved nutritional content. As agricultural biotechnology continues to evolve, the DNA Synthesis Market is expected to benefit from the demand for innovative solutions that address global food challenges. This trend suggests a promising future for the dna synthesis market as it aligns with the agricultural sector's goals.

### Increased Investment in Biotechnology

Investment in biotechnology is a key driver of the DNA Synthesis Market, as funding for biotech startups and established companies continues to rise. In 2025, venture capital investments in the US biotech sector are expected to exceed $20 billion, highlighting the growing confidence in the industry's potential. This influx of capital supports research and development activities, particularly in areas such as genomics and personalized medicine, which rely on advanced dna synthesis techniques. As biotechnology firms seek to innovate and bring new products to market, the demand for dna synthesis services is likely to grow, thereby strengthening the overall market.

## Future Outlook

The [DNA synthesis Market](https://www.marketresearchfuture.com/reports/dna-synthesis-market-20306) is projected to grow at a 30.75% CAGR from 2025 to 2035, driven by advancements in biotechnology, personalized medicine, and synthetic biology applications.

**New opportunities:**

- Development of custom DNA synthesis platforms for personalized therapeutics. Expansion of automated synthesis technologies for high-throughput applications. Partnerships with biotech firms for integrated genomic solutions.

By 2035, the DNA synthesis market is expected to achieve substantial growth, positioning itself as a leader in biotechnological innovation.

## Segment Insights

### By Application: Gene Therapy (Largest) vs. Synthetic Biology (Fastest-Growing)

In the US dna synthesis market, the application segment is prominently driven by gene therapy, which commands the largest market share due to its increasing adoption in clinical settings and ongoing advancements in technology. Synthetic biology follows as a rapidly growing segment, leveraging innovative approaches to redesign organisms for various applications, thus capturing significant interest and investment.

Current trends indicate robust growth within these applications, especially fueled by rising gene therapy funding and an expanding pipeline of synthetic biology solutions. The vaccine development segment is also gaining traction, driven by the urgency and necessity for novel vaccines, particularly in response to global health challenges. Furthermore, molecular diagnostics continue to evolve, enhancing precision medicine capabilities, and contributing positively to the overall dynamics of the application segment.

Gene Therapy (Dominant) vs. Vaccine Development (Emerging)

Gene therapy stands out as the dominant application within the US dna synthesis market, characterized by its potential to address genetic disorders and diseases through targeted interventions. This segment is bolstered by significant investments from both public and private sectors, leading to a wealth of new therapies being developed. In contrast, vaccine development is an emerging application, increasingly important in the wake of global health challenges such as pandemics. This segment is witnessing accelerated growth as organizations strive to develop more efficient and rapid vaccine solutions, driving collaboration across biotech and pharmaceutical sectors to enhance public health outcomes. Both segments represent critical advancements in biotechnology, reflecting the evolving landscape of healthcare and therapeutic approaches.

### By Product Type: Oligonucleotides (Largest) vs. Gene Libraries (Fastest-Growing)

In the US dna synthesis market, the distribution of market share among product types reveals that oligonucleotides hold a significant portion due to their wide application in diagnostic and therapeutic fields. Gene fragments and gene libraries, while important, occupy smaller shares, yet they are crucial for research purposes. The market is characterized by a strong demand for custom oligonucleotides, driven by advancements in personalized medicine and biotechnological innovations.

Growth trends indicate that while oligonucleotides continue to lead the market, gene libraries are emerging as the fastest-growing segment, fueled by the increasing demand for high-throughput sequencing and synthetic biology applications. The rapid advancements in gene synthesis technologies and an expanding user base in research institutions are key drivers of this growth, suggesting a dynamic shift towards gene libraries as critical tools in genomic research.

Oligonucleotides (Dominant) vs. Gene Libraries (Emerging)

Oligonucleotides are dominating the US dna synthesis market due to their extensive use in various applications, including diagnostics, therapeutics, and synthetic biology. Their flexibility allows for customization, enhancing their appeal to researchers and developers. On the other hand, gene libraries represent an emerging segment, gaining traction as they provide a comprehensive collection of genetic sequences for study and manipulation. This segment caters to the growing demands of genomics, enabling the discovery of novel genes and pathways. The integration of advanced technologies into gene library construction further supports their rapid market growth, making them essential tools for research and development.

### By End User: Pharmaceutical Companies (Largest) vs. Academic Research Institutions (Fastest-Growing)

The US dna synthesis market is segmented into four primary end users: Academic Research Institutions, Pharmaceutical Companies, Biotechnology Companies, and Clinical Laboratories. Among these, Pharmaceutical Companies hold the largest market share due to their extensive applications in drug development and personalized medicine. Academic Research Institutions have emerged as a significant segment as well, driven by the growing emphasis on genetic research and development.

Growth trends in the US dna synthesis market are notably influenced by the increasing focus on precision medicine and advancements in genomic research technology. Pharmaceutical Companies continue to invest heavily in synthetic DNA solutions, which enhances their research capabilities. Meanwhile, Academic Research Institutions are witnessing rapid growth as they adopt advanced synthesis technologies to support innovative studies, thereby positioning themselves as the fastest-growing segment within the market.

Pharmaceutical Companies (Dominant) vs. Academic Research Institutions (Emerging)

Pharmaceutical Companies dominate the US dna synthesis market mainly due to their substantial investment in research & development efforts, allowing for groundbreaking advancements in therapeutic solutions. They leverage cutting-edge dna synthesis technologies to create novel drugs tailored to specific patient needs, thus enhancing efficacy and safety. On the other hand, Academic Research Institutions are emerging rapidly as they prioritize DNA synthesis in their research activities. With increased funding and collaboration with biotech firms, these institutions are integrating advanced techniques into their curricula and research projects, thus contributing significantly to the growth and innovations in the market. This dynamic interplay between the two segments shapes a competitive landscape that encourages further advancements and applications.

### By Technology: Solid-Phase Synthesis (Largest) vs. PCR-Based Synthesis (Fastest-Growing)

In the US dna synthesis market, Solid-Phase Synthesis dominates the sector, capturing a significant share due to its efficiency and cost-effectiveness in producing high-quality oligonucleotides. Liquid-Phase Synthesis, while valuable, is being overshadowed by the rapid advancements in Solid-Phase techniques that offer superior scalability and automation capabilities.

On the other hand, PCR-Based Synthesis is recognized as the fastest-growing segment, driven by the increasing applications of PCR in diagnostics and research. The surge in demand for nucleic acids in therapeutic development and genetic research further propels the growth of this segment, making it a key area of focus for companies looking to innovate and capitalize on emerging market opportunities.

Technology: Solid-Phase Synthesis (Dominant) vs. PCR-Based Synthesis (Emerging)

Solid-Phase Synthesis is the leading technology in the market, characterized by its ability to produce oligonucleotides efficiently with a high degree of purity. This method enables modifications and complex sequences, which are essential for various applications, including gene synthesis and RNA interference. Conversely, PCR-Based Synthesis, while newer, is emerging rapidly due to its practical applications in research and clinical settings. This technology allows for the amplification of specific DNA sequences, making it invaluable for diagnostics and therapeutic innovations. Together, these methods represent the core technological advances shaping the landscape of the US dna synthesis market.

## Competitive Benchmarking

The dna synthesis market is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for synthetic biology applications. Key players such as Thermo Fisher Scientific (US), Illumina (US), and Twist Bioscience (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Thermo Fisher Scientific (US) focuses on innovation through extensive R&D investments, aiming to expand its product portfolio and improve synthesis efficiency. Illumina (US) emphasizes partnerships with academic institutions to foster innovation in genomic research, while Twist Bioscience (US) leverages its proprietary silicon-based DNA synthesis technology to offer cost-effective solutions, thereby reshaping competitive dynamics in the market.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Thermo Fisher Scientific (US) and Illumina (US) suggests a trend towards consolidation, as these firms seek to leverage economies of scale and enhance their competitive edge.
In September Thermo Fisher Scientific (US) announced a strategic partnership with a leading biotech firm to co-develop next-generation sequencing technologies. This collaboration is poised to accelerate innovation in the field, allowing Thermo Fisher to enhance its offerings and maintain a competitive advantage in the rapidly evolving market. The partnership underscores the importance of collaboration in driving technological advancements and meeting the growing demand for high-throughput sequencing solutions.
In October Illumina (US) launched a new line of synthesis products aimed at improving the accuracy and speed of genomic sequencing. This product line is expected to significantly enhance the capabilities of researchers and clinicians, positioning Illumina as a leader in the market. The introduction of these advanced products reflects Illumina's commitment to innovation and its strategic focus on addressing the evolving needs of the genomics community.
In August Twist Bioscience (US) expanded its manufacturing capabilities by opening a new facility dedicated to high-throughput DNA synthesis. This expansion is anticipated to increase production capacity and reduce lead times for customers, thereby enhancing Twist's competitive position. The move aligns with the growing demand for synthetic DNA in various applications, including therapeutics and diagnostics, and highlights the company's proactive approach to scaling operations in response to market needs.
As of November current competitive trends in the dna synthesis market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, supply chain reliability, and sustainable practices, reflecting the changing priorities of stakeholders in the industry.

## Recent News & Developments

The US DNA Synthesis Market has seen notable advancements and developments recently. In September 2023, Agilent Technologies announced its expansion of synthetic biology capabilities, strengthening its position within the market and enhancing service offerings for clients. Concurrently, Thermo Fisher Scientific introduced new advancements to its GeneArt suite, enabling faster and more efficient DNA synthesis, which is likely to contribute to increasing market demand. Merger and acquisition activities are also noteworthy, with Twist Bioscience acquiring a leading synthetic biology firm in August 2023, thereby broadening its product portfolio.

In the past couple of years, the market has witnessed significant growth, with a substantial increase in demand for custom DNA synthesis services due to rising investments in biotechnology and genomics, aligning with initiatives by the US government to promote innovation in life sciences. Companies like Illumina and Integrated DNA Technologies continue to expand their market presence through strategic collaborations and new product launches that address diverse needs within genomic research and therapeutic development. Overall, these factors contribute to a dynamic landscape in the US DNA Synthesis Market, reflective of ongoing technological advancements and increased applications in various sectors.

## Report Scope

| MARKET SIZE 2024 | 888.64(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1161.9(USD Million) |
| MARKET SIZE 2035 | 16960.94(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 30.75% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Illumina (US), Integrated DNA Technologies (US), Eurofins Genomics (DE), GenScript (CN), Twist Bioscience (US), Synthetic Genomics (US), Bioneer (KR), DNA Script (FR) |
| Segments Covered | Application, Product Type, End User, Technology |
| Key Market Opportunities | Advancements in personalized medicine drive demand for tailored solutions in the dna synthesis market. |
| Key Market Dynamics | Technological advancements drive innovation and competition in the DNA synthesis market, enhancing product offerings and efficiency. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US DNA synthesis market?**
A: The market valuation was $888.64 Million in 2024.

**Q: What is the projected market size for the US DNA synthesis market by 2035?**
A: The market is projected to reach $16,960.94 Million by 2035.

**Q: What is the expected CAGR for the US DNA synthesis market during the forecast period 2025 - 2035?**
A: The expected CAGR is 30.75% during the forecast period.

**Q: Which application segment holds the highest valuation in the US DNA synthesis market?**
A: The Synthetic Biology application segment was valued at $5,000 Million in 2024.

**Q: What are the key product types in the US DNA synthesis market?**
A: Key product types include Oligonucleotides, Gene Fragments, and Gene Libraries, with Gene Fragments valued at $6,700 Million in 2024.

**Q: Who are the leading companies in the US DNA synthesis market?**
A: Key players include Thermo Fisher Scientific, Illumina, Integrated DNA Technologies, and others.

**Q: What end-user segment contributed the most to the US DNA synthesis market in 2024?**
A: Biotechnology Companies contributed the most, with a valuation of $6,600.57 Million.

**Q: What technology segment is expected to drive growth in the US DNA synthesis market?**
A: PCR-Based Synthesis technology was valued at $6,960.94 Million in 2024.

**Q: How does the US DNA synthesis market compare across different end-user segments?**
A: Pharmaceutical Companies and Biotechnology Companies are leading, with valuations of $4,920.38 Million and $6,600.57 Million, respectively.

**Q: What trends are influencing the growth of the US DNA synthesis market?**
A: Trends include advancements in gene therapy, synthetic biology, and molecular diagnostics, which are expected to drive market expansion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-dna-synthesis-market-52769*